Cat. No.: DAB-0012910
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Applications | WB, IP |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro160 of human TIMM17A protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | TIMM17A |
| UniProt No. | Q99595 |
| Gene ID | 10440 |
| Gene Description | TIMM17A is a component of the TIM23 mitochondrial transport complex, the main translocase of mitochondrial matrix proteins. TIMM17A is a potential biomarker and therapeutic target in breast cancer, as high expression is associated with aggressiveness and poor prognosis. TIMM17A was identified as one of eleven genes included in a gene signature predictive of CDK4 phosphorylation, and of sensitivity to the CDK4/6 inhibitor Palbociclib. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
